105 related articles for article (PubMed ID: 11705128)
21. Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C.
Arguedas M
Pharmacoeconomics; 2004; 22(7):477-8; author reply 478-9. PubMed ID: 15137884
[No Abstract] [Full Text] [Related]
22. Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial.
Liu CH; Huang CF; Liu CJ; Dai CY; Liang CC; Huang JF; Hung PH; Tsai HB; Tsai MK; Chen SI; Lin JW; Yang SS; Su TH; Yang HC; Chen PJ; Chen DS; Chuang WL; Yu ML; Kao JH
Ann Intern Med; 2013 Dec; 159(11):729-38. PubMed ID: 24297189
[TBL] [Abstract][Full Text] [Related]
23. Cost-utility analysis of different peg-interferon alpha-2b plus ribavirin treatment strategies as initial therapy for naïve Chinese patients with chronic hepatitis C.
Lin WA; Tarn YH; Tang SL
Aliment Pharmacol Ther; 2006 Nov; 24(10):1483-93. PubMed ID: 17081165
[TBL] [Abstract][Full Text] [Related]
24. Cost minimisation analysis of 12 or 24 weeks of peginterferon alfa-2b + ribavirin for hepatitis C virus.
De Compadri P; Koleva D; Mangia A; Motterlini Stat Sci N; Garattini L
J Med Econ; 2008; 11(1):151-63. PubMed ID: 19450116
[TBL] [Abstract][Full Text] [Related]
25. Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review.
Shepherd J; Waugh N; Hewitson P
Health Technol Assess; 2000; 4(33):1-67. PubMed ID: 11134916
[TBL] [Abstract][Full Text] [Related]
26. [Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection].
Hunyady B; Kovács B; Battyáni Z
Orv Hetil; 2011 Dec; 152(50):1997-2009. PubMed ID: 22112373
[TBL] [Abstract][Full Text] [Related]
27. Financial impact of two different ways of evaluating early virological response to peginterferon-alpha-2b plus ribavirin therapy in treatment-naive patients with chronic hepatitis C virus genotype 1.
Buti M; Casado MA; Fosbrook L; Esteban R
Pharmacoeconomics; 2005; 23(10):1043-55. PubMed ID: 16235977
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection.
Hornberger J; Torriani FJ; Dieterich DT; Bräu N; Sulkowski MS; Torres MR; Green J; Patel K
J Clin Virol; 2006 Aug; 36(4):283-91. PubMed ID: 16765638
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy.
Del Rio RA; Post AB; Singer ME
Hepatology; 2006 Dec; 44(6):1598-606. PubMed ID: 17133490
[TBL] [Abstract][Full Text] [Related]
30. A health economic model to assess the long term effects and cost-effectiveness of PEG IFN alpha-2a in hepatitis C virus infected patients.
Annemans L; Warie H; Nechelput M; Peraux B
Acta Gastroenterol Belg; 2004; 67(1):1-8. PubMed ID: 15149079
[TBL] [Abstract][Full Text] [Related]
31. [Cost-utility analysis of triple therapy with telaprevir in treatment-naïve hepatitis C patients].
Buti M; Gros B; Oyagüez I; Andrade RJ; Serra MA; Turnes J; Casado MA
Farm Hosp; 2014 Sep; 38(5):418-29. PubMed ID: 25344136
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of peginterferon alfa-2b in combination with ribavirin as initial treatment for chronic hepatitis C in Sweden.
Bernfort L; Sennfält K; Reichard O
Scand J Infect Dis; 2006; 38(6-7):497-505. PubMed ID: 16798701
[TBL] [Abstract][Full Text] [Related]
33. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients.
Maddrey WC
Semin Liver Dis; 1999; 19 Suppl 1():67-75. PubMed ID: 10349694
[TBL] [Abstract][Full Text] [Related]
34. Hepatitis C in adults and adolescents with hemophilia: a randomized, controlled trial of interferon alfa-2b and ribavirin.
Fried MW; Peter J; Hoots K; Gaglio PJ; Talbut D; Davis PC; Key NS; White GC; Lindblad L; Rickles FR; Abshire TC
Hepatology; 2002 Oct; 36(4 Pt 1):967-72. PubMed ID: 12297845
[TBL] [Abstract][Full Text] [Related]
35. A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C.
Carrión JA; Gonzalez-Colominas E; García-Retortillo M; Cañete N; Cirera I; Coll S; Giménez MD; Márquez C; Martin-Escudero V; Castellví P; Navinés R; Castaño JR; Galeras JA; Salas E; Bory F; Martín-Santos R; Solà R
J Hepatol; 2013 Nov; 59(5):926-33. PubMed ID: 23811030
[TBL] [Abstract][Full Text] [Related]
36. Epoetin alfa treatment for acute anaemia during interferon plus ribavirin combination therapy for chronic hepatitis C.
Bräu N
J Viral Hepat; 2004 May; 11(3):191-7. PubMed ID: 15117320
[TBL] [Abstract][Full Text] [Related]
37. Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C.
Scott LJ; Perry CM
Drugs; 2002; 62(3):507-56. PubMed ID: 11827565
[TBL] [Abstract][Full Text] [Related]
38. ITPA genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response.
Holmes JA; Roberts SK; Ali RJ; Dore GJ; Sievert W; McCaughan GW; Crawford DH; Cheng WS; Weltman MD; Bonanzinga S; Visvanathan K; Sundararajan V; Desmond PV; Bowden DS; Matthews GV; Thompson AJ;
Hepatology; 2014 Jun; 59(6):2152-60. PubMed ID: 24449403
[TBL] [Abstract][Full Text] [Related]
39. Acute hepatitis C: a 24-week course of pegylated interferon α-2b versus a 12-week course of pegylated interferon α-2b alone or with ribavirin.
Santantonio T; Fasano M; Sagnelli E; Tundo P; Babudieri S; Fabris P; Toti M; Di Perri G; Marino N; Pizzigallo E; Angarano G;
Hepatology; 2014 Jun; 59(6):2101-9. PubMed ID: 24442928
[TBL] [Abstract][Full Text] [Related]
40. Interferon-alpha-2b + ribavirin for the treatment of chronic hepatitis C in non-responders to interferon-alpha-monotherapy.
Tromm A; Greving I; Griga T; Mankel K; Hüppe D
Z Gastroenterol; 2000 Feb; 38(2):159-64. PubMed ID: 10721171
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
